Aeglea BioTherapeutics Employee Directory
Biotechnology ResearchTexas, United States11-50 Employees
Aeglea BioTherapeutics is a biotechnology research company based in Austin, Texas. It has shifted its disease focus to inflammatory bowel disease following the acquisition of Spyre Therapeutics. Spyre Therapeutics brings capabilities in antibody engineering, rational therapeutic combinations, and precision immunology intended to enhance the effectiveness, safety, and convenience of IBD treatments. The move aligns Aeglea with Spyre’s program to pursue therapies for this disease area. The company targets patients with inflammatory bowel disease and the clinicians who treat them by pursuing more effective therapeutic options. In 2023, the organization announced a name change to Spyre Therapeutics and expanded its leadership to develop next-generation therapeutic combinations for inflammatory bowel disease.